The company that makes Tylenol is pushing back against a proposed safety warning on labels for all drugs containing acetaminophen. A petition filed with the U.S. Food and Drug Administration calls for labels to state that, if taken during pregnancy, the medication may increase a child’s risk of neurodevelopmental disorders, including autism. 

A McGill University expert is available to comment on this topic: 

Robert Platt  is the Director of the School of Population and Global Health and a Professor in the Department of Epidemiology, Biostatistics and Occupational Health. He can speak to the scientific evidence refuting the U.S. president’s claims linking Tylenol use during pregnancy to autism, including a  new study he co-authored  published in the Journal of the American Academy of Child & Adolescent Psychiatry  that found no convincing evidence to support such a link. 

robert.platt [at] mcgill.ca  (English, French)